77 related articles for article (PubMed ID: 31787337)
21. Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay.
Mateoiu C; Vitiazeva V; Kristjansdottir B; Weijdegård B; Örnros J; Gallini R; Kamali-Moghaddam M; Sundfeldt K; Karlsson NG
Glycobiology; 2021 Dec; 31(11):1464-1471. PubMed ID: 34459484
[TBL] [Abstract][Full Text] [Related]
22. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
[TBL] [Abstract][Full Text] [Related]
23. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.
Terävä J; Tiainen L; Lamminmäki U; Kellokumpu-Lehtinen PL; Pettersson K; Gidwani K
PLoS One; 2019; 14(7):e0219480. PubMed ID: 31344060
[TBL] [Abstract][Full Text] [Related]
24. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3.
Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
[TBL] [Abstract][Full Text] [Related]
26. Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection.
Kekki H; Peltola M; van Vliet S; Bangma C; van Kooyk Y; Pettersson K
Clin Biochem; 2017 Jan; 50(1-2):54-61. PubMed ID: 27818346
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
[TBL] [Abstract][Full Text] [Related]
28. Glycosylation markers in cancer.
Silsirivanit A
Adv Clin Chem; 2019; 89():189-213. PubMed ID: 30797469
[TBL] [Abstract][Full Text] [Related]
29. Glycosylation products in prostate diseases.
Dos Santos Silva PM; Albuquerque PBS; de Oliveira WF; Coelho LCBB; Dos Santos Correia MT
Clin Chim Acta; 2019 Nov; 498():52-61. PubMed ID: 31400314
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer.
Yang F; Tang J; Zhao Z; Zhao C; Xiang Y
Reprod Biol Endocrinol; 2021 Dec; 19(1):178. PubMed ID: 34861867
[TBL] [Abstract][Full Text] [Related]
32. Early detection of ovarian cancer.
Badgwell D; Bast RC
Dis Markers; 2007; 23(5-6):397-410. PubMed ID: 18057523
[TBL] [Abstract][Full Text] [Related]
33. Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques.
Haga Y; Ueda K
Glycoconj J; 2022 Apr; 39(2):303-313. PubMed ID: 35156159
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
